肺原位腺癌的诊断与治疗进展  

Advance in Diagnose and Treatment Strategies of Adenocarcinoma in Situ

作　　者：裘杨波 申屠阳[1] 

机构地区：[1]上海交通大学附属胸科医院/上海市肺部肿瘤临床医学中心,上海200039

出　　处：《中国肺癌杂志》2017年第9期641-644,共4页Chinese Journal of Lung Cancer

摘　　要：肺原位腺癌(adenocarcinoma in situ,AIS)于2011年在肺腺癌国际多学科分类中新增,2015版世界卫生组织(World Health Organization,WHO)肺肿瘤分类中补充,由于AIS处于肺腺癌发展的早期阶段,加深对其病理、诊断、鉴别与治疗策略等方面的认识,对改善肺腺癌的治疗预后具有重要意义。本综述将对目前AIS的发生发展、病理特征、鉴别诊断和治疗策略等方面的研究做一系统回顾,旨在为AIS的进一步研究提供理论基础。Adenocarcinoma in situ（AIS） is a new concept which was introduced to the 2011 The International Association for the Study of Cancer（IASLC）/American Thoracic Society（ATS）/European Respiratory Society（ERS） International Multidisciplinary Classification of Lung Adenocarcinoma firstly and an important supplement of The 2015 World Health Organization Classification of Lung Tumors. Because AIS is at an early stage of development of lung adenocarcinoma, the deepening understanding of its pathology, differential diagnosis, treatment strategies, has an important significance for the improvement of the prognosis of lung adenocarcinoma. This review will provide a systematic review of the main progress of occurrence and development, pathological characteristics, differential diagnosis and treatment strategy of AIS, in order to provide theoretical basis for the further research of AIS.

关 键 词：肺原位腺癌 病理特征 诊断 治疗 

分 类 号：R734.2[医药卫生—肿瘤]